Cargando…

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection

BACKGROUND: In separate phase 2 trials, 120 patients received maribavir for cytomegalovirus (CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for asymptomatic infection (trial 203). Overall, 172 cleared their CMV infection (CMV DNA <200 copies/mL) within 6 weeks....

Descripción completa

Detalles Bibliográficos
Autores principales:	Chou, Sunwen, Song, Kening, Wu, Jingyang, Bo, Tien, Crumpacker, Clyde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441206/ https://www.ncbi.nlm.nih.gov/pubmed/32726419 http://dx.doi.org/10.1093/infdis/jiaa462

Ejemplares similares

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial( )
por: Avery, Robin K, et al.
Publicado: (2021)

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
por: Gill, Rachel B, et al.
Publicado: (2009)

Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
por: Gandhi, Ronak G, et al.
Publicado: (2022)

Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with Cytomegalovirus
por: Houldcroft, Charlotte J., et al.
Publicado: (2016)

The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein
por: Shannon-Lowe, Claire D, et al.
Publicado: (2010)

Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient
por: Schubert, Axel, et al.
Publicado: (2013)

Maribavir for Cytomegalovirus Treatment in the Real World—Not a Silver Bullet
por: Fung, Monica, et al.
Publicado: (2022)

Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis
por: Lanier, E. Randall, et al.
Publicado: (2016)

Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study
por: Ilic, Katarina, et al.
Publicado: (2020)

21. Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results
por: Pereira, Marcus, et al.
Publicado: (2021)

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
por: Papanicolaou, Genovefa A, et al.
Publicado: (2019)

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus
por: Sun, Kefeng, et al.
Publicado: (2023)

Correction to: Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
Publicado: (2023)

Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-Generation Sequencing
por: Lodding, Isabelle P, et al.
Publicado: (2021)

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
por: Song, Ivy, et al.
Publicado: (2022)

Viral and Cell Cycle–Regulated Kinases in Cytomegalovirus-Induced Pseudomitosis and Replication
por: Hertel, Laura, et al.
Publicado: (2007)

Cytomegalovirus Infection Causes an Increase of Arterial Blood Pressure
por: Cheng, Jilin, et al.
Publicado: (2009)

Synthesis of New Imidazopyridine Nucleoside Derivatives Designed as Maribavir Analogues
por: Papadakis, Georgios, et al.
Publicado: (2020)

Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection
por: Faure Bardon, Valentine, et al.
Publicado: (2020)

Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers
por: Song, Ivy H., et al.
Publicado: (2019)

Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency
por: Popping, Stephanie, et al.
Publicado: (2019)

S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
por: Duarte, Rafael F, et al.
Publicado: (2023)

Analysis of Ganciclovir-Resistant Cytomegalovirus Infection Caused by the UL97 Gene Mutation in Codons 460 and 520 in Pediatric Patients: A Case Series
por: Boonsathorn, Sophida, et al.
Publicado: (2019)

Cytomegalovirus DNAemia Requiring (Val)Ganciclovir Treatment for More Than 8 Weeks Is a Key Factor in the Development of Antiviral Drug Resistance
por: Acquier, M, et al.
Publicado: (2023)

Eradication of HIV and Cure of AIDS, Now and How?
por: Zhang, Jielin, et al.
Publicado: (2013)

Hematopoietic Stem and Immune Cells in Chronic HIV Infection
por: Zhang, Jielin, et al.
Publicado: (2015)

Toward a Cure: Does Host Immunity Play a Role?
por: Zhang, Jielin, et al.
Publicado: (2017)

HIV UTR, LTR, and Epigenetic Immunity
por: Zhang, Jielin, et al.
Publicado: (2022)

Association of Cytomegalovirus DNA and Immunologic Markers of Cardiovascular Disease
por: Garg, Ankita, et al.
Publicado: (2019)

A Prospective Study of Cytomegalovirus-Specific Cell-Mediated Immune Monitoring and Cytomegalovirus Infection in Patients With Active Systemic Lupus Erythematosus Receiving Immunosuppressants
por: Bruminhent, Jackrapong, et al.
Publicado: (2021)

In Utero Activation of Natural Killer Cells in Congenital Cytomegalovirus Infection
por: Vaaben, Anna V, et al.
Publicado: (2022)

The Excess Burden of Cytomegalovirus in African American Communities: A Geospatial Analysis
por: Lantos, Paul M., et al.
Publicado: (2015)

Cytomegalovirus drug resistance mutations in transplant recipients with suspected resistance
por: Recio, Vanessa, et al.
Publicado: (2023)

Systems Vaccinology in HIV Vaccine Development
por: Zhang, Jielin, et al.
Publicado: (2022)

Human Cytomegalovirus Up-Regulates Endothelin Receptor Type B: Implication for Vasculopathies?
por: Yaiw, Koon-Chu, et al.
Publicado: (2015)

Molecular and Culture-Based Bronchoalveolar Lavage Fluid Testing for the Diagnosis of Cytomegalovirus Pneumonitis
por: Tan, Susanna K., et al.
Publicado: (2016)

Cardiac Microvascular Dysfunction in Women Living With HIV Is Associated With Cytomegalovirus Immunoglobulin G
por: Knudsen, Andreas, et al.
Publicado: (2018)

Cytomegalovirus Latent Infection is Associated with an Increased Risk of COVID-19-Related Hospitalization
por: Alanio, Cécile, et al.
Publicado: (2022)

Outcomes of Cytomegalovirus Viremia Treatment in Critically Ill Patients With COVID-19 Infection
por: Schoninger, Scott, et al.
Publicado: (2022)

Cytomegalovirus Viremia Predicts Postdischarge Mortality in Kenyan HIV-Exposed Uninfected Children( )
por: Pavlinac, Patricia B, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lnpudkbsq3u3m1nh0k81a873rb